Survival, toxicity, and sequencing: navigating the new first-line standard established by FLAURA2

The management of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations has seen steady progress, moving from first-generation tyrosine kinase inhibitors (TKIs) to the third-generation agent osimertinib. The phase 3 FLAURA trial established osimertinib monotherapy as a global standard, demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to earlier TKIs. However, resistance eventually develops, and many patients—often 25% to 40%—do not reach second-line therapy due to rapid clinical decline (1).

The phase 3 FLAURA2 trial was initiated to test whether an upfront combination of osimertinib and platinum-pemetrexed chemotherapy could provide deeper disease control and extend life beyond what is possible with TKI monotherapy. Early results from FLAURA2 successfully met the primary endpoint, showing a significant investigator-assessed PFS benefit [25.5 vs. 16.7 months; hazard ratio (HR) 0.62] (2). While these data were enough to change clinical practice and gain regulatory approvals, the definitive confirmation of this intensified approach rested on the final OS analysis. The results published in the New England Journal of Medicine in early 2026 provide that landmark evidence, setting a new benchmark for frontline survival in this patient population (3).

FLAURA2 OS landmark

In this final analysis, with a median follow-up of over 51 months, the combination of osimertinib and chemotherapy demonstrated a statistically significant extension in survival (3). The median OS reached 47.5 months in the combination arm compared to 37.6 months in the monotherapy arm. This absolute gain of nearly 10 months represents the longest median OS ever reported in a global phase 3 trial for frontline EGFR-mutated NSCLC. The HR for death was 0.77 [95% confidence interval (CI), 0.61–0.96; P=0.02], indicating a 23% reduction in the risk of death.

Crucially, this survival advantage was maintained even though the control arm received heavy subsequent therapy. Approximately 77% of patients in the monotherapy group received a second-line treatment, with 72% of those receiving platinum-based chemotherapy. Notably, the Japanese subset, a population known for high access to subsequent platinum-based chemotherapy, also demonstrated a consistent OS benefit (HR 0.60; 95% CI, 0.36–1.03). This robust finding underscores that the timing of chemotherapy is critical; delivering it concurrently with the TKI at the start of treatment provides a benefit that cannot be fully captured by waiting for disease progression. This “intensive upfront” strategy appears to effectively suppress resistant clones that might otherwise lead to rapid progression, while simultaneously preventing the rapid clinical deterioration that often compromises the delivery of second-line chemotherapy. While the concept of concurrent administration to eradicate heterogeneous clones was previously explored with first-generation TKIs, yielding improved PFS but ultimately failing to demonstrate a definitive OS benefit (4), the success of FLAURA2 suggests that the superior potency and central nervous system (CNS) penetration of a third-generation TKI are essential to fully realize the survival potential of this synergistic approach.

Strategic gains in high-risk subgroups: brain metastases and L858R

The most compelling clinical arguments for the combination therapy are found in patients with traditionally poor prognostic factors. CNS metastases and the L858R mutation have long presented challenges to TKI monotherapy, and FLAURA2 offers promising data, though subject to subgroup limitations discussed later in this section, for bridging these efficacy gaps.

Brain metastases occur in up to 40% of patients during their disease course (5,6). While osimertinib monotherapy has excellent CNS penetration, the addition of chemotherapy significantly improves outcomes. Osimertinib plus chemotherapy significantly improved CNS PFS with a HR of 0.58 (7); however, it should be noted that unlike the MARIPOSA trial, FLAURA2 did not mandate routine serial brain imaging for all patients, which is an important methodological distinction when interpreting these data. Furthermore, this final analysis also demonstrated that the OS benefit was consistent regardless of baseline CNS metastases (3). For patients with CNS metastases, the 3-year survival rate was 57% versus 40% (HR 0.72). Similarly, patients without CNS metastases achieved a 3-year survival rate of 67% compared to 58% with monotherapy (HR 0.77). For clinicians, this makes the FLAURA2 regimen a preferred choice for patients with brain involvement to maximize disease control, bolstered by higher rates of complete CNS responses, and potentially delay local interventions like radiation.

The L858R mutation has historically shown lower sensitivity to TKIs compared to exon 19 deletions, resulting in shorter survival in real-world registries (8). FLAURA2 provides a meaningful improvement for this subgroup. In patients with the L858R mutation, the combination therapy demonstrated a significant PFS benefit with a HR of 0.63 (95% CI, 0.44–0.90). This efficacy is comparable to that observed in patients with Exon 19 deletion (HR 0.60), indicating consistent benefits across these EGFR mutation subtypes (2). Moreover, in this final analysis, patients with L858R mutations achieved a median OS of 38.1 months with the combination versus 32.4 months with monotherapy (HR 0.76) (3). The 3-year OS rate was also higher at 54% compared to 42%. These results suggest that chemotherapy helps mitigate, though does not completely overcome, the biological limitations of targeted therapy alone in L858R cases, highlighting the need for continued therapeutic advances for these high-risk populations. Importantly, this enhanced efficacy in high-risk subgroups aligns with historical observations from earlier first-generation TKI combinations, suggesting that the broad cytotoxic effect of chemotherapy generally helps address the inherent genomic heterogeneity and co-mutations that drive poorer outcomes in these specific populations.

However, several limitations of the FLAURA2 data must be acknowledged. Most importantly, while the CNS and L858R subgroups showed strong results, they were not pre-randomization stratification factors. This means that while the subgroups were generally well-balanced, they were not formally controlled for at the start of the study. Therefore, while the clinical indications for the FLAURA2 regimen derived from this subgroup analysis are promising, they must be interpreted with caution. Accumulating large-scale real-world data and confirming the reproducibility of these findings will be essential.

Balancing efficacy with toxicity and quality of life

The survival benefits of FLAURA2 must be balanced against the increased toxicity inherent in adding chemotherapy. Grade 3 or higher adverse events (AEs) were more frequent in the combination arm (70% vs. 34%), primarily due to hematologic events like anemia and neutropenia. However, these toxicities were mostly manageable and occurred predominantly during the initial 12-week platinum induction phase.

The patient-reported outcomes (PROs) analysis from FLAURA2 shows that overall Quality of Life was generally maintained in both groups (9). However, looking at the changes in EORTC-QLQ-C30 and QLQ-LC13 scores, the addition of chemotherapy showed a trend toward deterioration in fatigue and appetite loss. Since many patients with EGFR-mutated NSCLC are relatively young, these symptoms can significantly hinder their ability to work and maintain a daily routine. Furthermore, the requirement for regular intravenous administration introduces significant “time toxicity”, adding a logistical burden of frequent hospital visits that contrasts sharply with the convenience of oral monotherapy. This raises a critical question: is the addition of chemotherapy truly necessary for all patients? In real-world practice, this intensive combination may not be feasible or appropriate for frail patients or those with significant comorbidities. Therefore, careful patient selection based on overall clinical fitness is required, and proactive management of AEs is essential to support their work-life balance. Moving forward, addressing unanswered clinical questions, such as the appropriate timing for treatment de-escalation, the optimal duration of pemetrexed maintenance, and the potential role of ctDNA in guiding these decisions, will be vital to mitigating long-term toxicity and preserving quality of life.

Optimizing treatment selection: FLAURA2 versus MARIPOSA

As the treatment landscape evolves, the FLAURA2 results now sit alongside those of the MARIPOSA trial, which demonstrated a similar survival benefit using a different intensification strategy: the bispecific antibody amivantamab plus the third-generation EGFR-TKI lazertinib (10). However, it is imperative to emphasize that in the absence of head-to-head prospective trials, any direct comparisons between these two distinct strategies must be interpreted with caution.

Regarding efficacy, the amivantamab plus lazertinib regimen appears to show limited benefit for the L858R subgroup. While the FLAURA2 regimen demonstrated consistent efficacy for L858R, amivantamab plus lazertinib resulted in a PFS HR of 0.78 (95% CI, 0.59–1.02) for this subgroup, indicating a less pronounced benefit compared to the Exon 19 deletion subgroup (HR 0.65). A similar divergence was observed in OS; the HR for L858R was 0.90 (95% CI, 0.67–1.21), suggesting a disparity in survival benefit compared to the HR of 0.66 (95% CI, 0.50–0.86) seen in the Exon 19 deletion subgroup. This difference in efficacy for L858R could be a key factor when choosing between these two excellent regimens in clinical practice. However, it is important to note that, unlike MARIPOSA, the FLAURA2 study did not use EGFR mutation subtype as a stratification factor. Therefore, we must interpret these results with caution and await further verification through the accumulation of real-world data.

Beyond efficacy, while both regimens demonstrated statistically significant improvements in PFS and OS compared to osimertinib monotherapy, though differences in subsequent therapy access and crossover limit direct cross-trial survival comparisons, their toxicity profiles differ significantly. FLAURA2 is characterized by myelosuppression and gastrointestinal toxicities, while MARIPOSA is associated with high frequencies of skin toxicities (paronychia and rash), peripheral edema, venous thromboembolism, and infusion-related reactions (IRRs). Notably, the rash presents with atypical morphological features and distribution compared to conventional EGFR-TKIs. To address these concerns, proactive supportive care strategies have been established, such as prophylactic anticoagulation for thrombosis and dermatological management (e.g., minocycline) (11). Furthermore, the subcutaneous formulation has been approved, offering reduced risks of IRR, along with significantly shorter administration times (12). However, it must be noted that the subcutaneous formulation does not reduce the frequency or severity of dermatological toxicities. Given that the EGFR-mutated NSCLC population includes many younger and female patients, the physical and psychological impact of AEs from the first-line treatment is profound. Therefore, clinicians must take this to heart and focus on two key areas: First, we must strive for early detection and appropriate dose management (interruption or reduction) in close cooperation with patients. Second, the practice of shared decision making is indispensable. This ensures that each patient can confidently select the treatment option that best aligns with their values and lifestyle.

Future directions: second-line therapies and beyond

Finally, we turn to the evolving landscape of second-line treatment after osimertinib failure. First, the combination of amivantamab and chemotherapy has already established itself as a standard option, having demonstrated significant PFS benefits in the MARIPOSA-2 trial (13). Second, progress in resistance-matched therapies is accelerating. The combination of savolitinib and osimertinib is generating promising data for patients with MET amplification or overexpression (14,15). With evidence from pivotal trials accumulating, this regimen is expected to gain regulatory approval in various countries in the near future. Third, antibody-drug conjugates targeting TROP2, such as datopotamab deruxtecan and sacituzumab tirumotecan, are emerging as promising therapeutic options in this setting (16,17).

However, the choice of future therapies may depend heavily on the initial treatment strategy. Analysis of resistance mechanisms reveals that while the resistance profile following osimertinib plus chemotherapy largely mirrors the spectrum of osimertinib monotherapy, the frequency of identified alterations is generally lower. Specifically, secondary EGFR mutations (4% vs. 16%) and MET amplification (9% vs. 14%) were less frequent in the combination arm. This trend is even more pronounced with the amivantamab plus lazertinib regimen, which suppresses MET amplification (4%) and secondary EGFR mutations (1%) to an even greater extent, although it is distinguished by a higher incidence of HER2 amplification (19%) (18). Alongside these genomic alterations, non-genomic resistance, particularly histologic transformation to small cell lung cancer (SCLC), remains a crucial clinical consideration. Furthermore, it is notable that both combination strategies were associated with a higher proportion of resistance mechanisms classified as ‘unknown’ compared to osimertinib monotherapy (49%). Specifically, this rate reached 75% for osimertinib plus chemotherapy and 68% for amivantamab plus lazertinib. Elucidating the nature of these unknown mechanisms is a critical priority to facilitate future drug development.

Ultimately, these divergences underscore the need to tailor second-line strategies to the specific resistance patterns induced by the first-line regimen. As these evolving therapies will inevitably play a crucial role in prolonging OS, we are likely entering an era where the choice of first-line treatment must be driven by a strategic consideration of the entire therapeutic sequence. To avoid the “attraction bias” of upfront intensification and potential overtreatment, sequential strategies, such as continuing osimertinib with the addition of chemotherapy upon progression, an approach evaluated in the phase 3 COMPEL trial (19), may represent a pragmatic alternative to preserve tolerability and subsequent therapeutic options.

Conclusions

The OS analysis of FLAURA2 marks a pivotal moment in the management of EGFR-mutated NSCLC, establishing the longest survival benchmark reported to date. While the addition of chemotherapy offers profound benefits—particularly for patients with L858R mutations or CNS metastases—it introduces a trade-off with toxicity that necessitates careful patient selection, consideration of healthcare access, and shared decision-making. As the therapeutic landscape expands to include diverse second-line options, the initial treatment decision must now be viewed as the foundation of a sequential strategy. Ultimately, the FLAURA2 regimen stands as a powerful standard of care that, when applied judiciously, provides the opportunity for significantly extended survival in this patient population.

Acknowledgments

We would like to express our sincere gratitude to Miki Kajiwara, Ichiko Yamashita, and Wakana Tamura (Department of Thoracic Oncology, Kansai Medical University, Japan) for their efforts in data collection.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Translational Lung Cancer Research. The article has undergone external peer review.

Peer Review File: Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-1-0190/prf

Funding: None.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2026-1-0190/coif). S.I. received research funding from AstraZeneca and Chugai Pharmaceutical; honoraria for lectures from AstraZeneca, Chugai Pharmaceutical, Bristol Myers Squibb, Ono Pharmaceutical, Taiho Pharmaceutical, Nippon Boehringer Ingelheim, Eli Lilly, Takeda Pharmaceutical, Pfizer, MSD, Daiichi Sankyo, Amgen, Novartis, and Regeneron; and took on a consulting or advisory roles for AstraZeneca, Chugai Pharmaceutical, and Daiichi Sankyo. T.K. received research funding from MSD, AstraZeneca, Amgen, Boehringer Ingelheim, Daiichi Sankyo, Takeda Pharmaceutical, and Bristol Myers Squibb; and honoraria for lectures from AstraZeneca, Ono Pharmaceutical, MSD, Nippon Kayaku, Takeda Pharmaceutical, Eli Lilly, Bristol Myers Squibb, Chugai Pharmaceutical, Pfizer, and Janssen Pharmaceutical. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Roeper J, Kurz S, Grohé C, et al. Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. Future Oncol 2021;17:471-86. [Crossref] [PubMed]
2. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med 2023;389:1935-48. [Crossref] [PubMed]
3. Jänne PA, Planchard D, Kobayashi K, et al. Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med 2026;394:27-38. [Crossref] [PubMed]
4. Miyauchi E, Morita S, Nakamura A, et al. Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR. J Clin Oncol 2022;40:3587-92. [Crossref] [PubMed]
5. Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci 2016;107:1179-86. [Crossref] [PubMed]
6. Leduc C, Merlio JP, Besse B, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol 2017;28:2715-24. [Crossref] [PubMed]
7. Jänne PA, Planchard D, Kobayashi K, et al. CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2024;42:808-20. [Crossref] [PubMed]
8. Sakata Y, Sakata S, Oya Y, et al. Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT). Eur J Cancer 2021;159:144-53. [Crossref] [PubMed]
9. Lee CK, Cheng Y, Laktionov K, et al. First-line osimertinib ± platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs). ESMO Open 2024;9:102588. [Crossref]
10. Cho BC, Lu S, Felip E, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med 2024;391:1486-98. [Crossref] [PubMed]
11. Cho BC, Li W, Spira AI, et al. Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial. J Thorac Oncol 2025;20:1517-30. [Crossref] [PubMed]
12. Leighl NB, Akamatsu H, Lim SM, et al. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol 2024;42:3593-605. [Crossref] [PubMed]
13. Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol 2024;35:77-90. [Crossref] [PubMed]
14. Lu S, Wang J, Yang N, et al. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2026;407:375-87. [Crossref] [PubMed]
15. de Marinis F, Kim TM, Bonanno L, et al. Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. Ann Oncol 2025;36:920-33. [Crossref] [PubMed]
16. Ahn MJ, Lisberg A, Goto Y, et al. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. J Thorac Oncol 2025;20:1669-82. [Crossref] [PubMed]
17. Fang W, Wu L, Meng X, et al. Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. N Engl J Med 2026;394:13-26. [Crossref] [PubMed]
18. Gomez-Randulfe I, Monaca F, Planchard D, et al. Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations. Crit Rev Oncol Hematol 2025;212:104762. [Crossref] [PubMed]
19. Peled N, Tufman A, Sequist LV, et al. COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib. ESMO Open 2025;10:105807. [Crossref] [PubMed]